Make us your home page
Instagram

Today’s top headlines delivered to you daily.

(View our Privacy Policy)

USF researchers get closer to a cure while studying why arthritis prevents Alzheimer's

It has been known for some years that people who suffer from rheumatoid arthritis are less likely to develop Alzheimer's disease.

But now, researchers at the University of South Florida think they know why, and their findings could pave the way for a treatment for the disease.

The researchers found that a protein released into the bloodstream of people with rheumatoid arthritis provided protection against Alzheimer's in mice.

Their study appears online today in the Journal of Alzheimer's Disease.

One of the next steps could be testing the protein, known as GM-CSF, on humans. Huntington Potter, the principal investigator, noted that the man-made form of GM-CSF, known as Leukine, is already approved by the FDA to treat certain cancer patients who need to generate more immune cells.

"Our study, along with the drug's track record for safety, suggests Leukine should be tested in humans as a potential treatment for Alzheimer's disease," said Potter, a professor of molecular medicine at USF Health Byrd Alzheimer's Institute and director of the Florida Alzheimer's Disease Research Center.

People with rheumatoid arthritis — a disease that leads to inflammation of the joints and surrounding tissues — are less likely to develop Alzheimer's. It had been assumed that the non-steroidal anti-inflammatory drugs they were taking helped prevent the onset and progression of Alzheimer's. But recent clinical trials proved this was not the case.

So, USF researchers then looked at other explanations. They analyzed three growth factors of rheumatoid arthritis in mice that have been bred to develop Alzheimer's symptoms, and identified the protein GM-CSF as the most promising for protection against Alzheimer's. A 20-day study confirmed that the mice treated with GM-CSF performed better on tests measuring memory and learning than mice that were given a placebo. In fact, the memories in the treated mice were similar to normal-aged mice without dementia.

"We were pretty amazed that the treatment completely reversed cognitive impairment in 20 days," Tim Boyd, one of the lead authors of the study, said in a news release.

But success in mice doesn't necessarily mean the treatment will be beneficial to humans. Researchers have alleviated Alzheimer's-like symptoms in mice several times over, only to learn that the same treatment did not work in humans.

"It's essential people keep in mind that mice are not people," said Bill Thies, chief medical and scientific officer with the national Alzheimer's Association.

"Mice stay in their cages, eat their mice chow, and are of a very consistent genetic background," Thies said, while humans are much more complicated.

But at the same time, Thies said animal testing is essential. "It gives us the possibilities we can examine in humans."

Potter says there's reason for "cautious optimism" about the latest finding. He says it's the combination of knowing that the protein GM-CSF is released during rheumatoid arthritis, and that those patients are protected against Alzheimer's; that the man-made form of the protein, Leukine, has been proven safe over nearly 20 years of use; and that the mouse study has shown benefits of using the protein.

"We expect there to be no problem setting up a clinical trial," Potter said.

USF researchers get closer to a cure while studying why arthritis prevents Alzheimer's 08/22/10 [Last modified: Sunday, August 22, 2010 11:25pm]
Photo reprints | Article reprints

© 2017 Tampa Bay Times

    

Join the discussion: Click to view comments, add yours

Loading...
  1. No. 16 USF hangs on at Tulane, off to first 7-0 start

    College

    NEW ORLEANS — After half a season of mismatches, USF found itself in a grudge match Saturday night.

    USF quarterback Quinton Flowers (9) runs for a touchdown against Tulane during the first half of an NCAA college football game in New Orleans, La., Saturday, Oct. 21, 2017. (AP Photo/Derick E. Hingle) LADH103
  2. Lightning buries Penguins (w/video)

    Lightning Strikes

    TAMPA — Ryan Callahan spent a lot of time last season rehabilitating his injured hip alongside Steven Stamkos, who was rehabbing a knee after season-ending surgery. During those hours, Callahan noticed two things about Stamkos: his hunger and his excitement to return this season.

    Tampa Bay Lightning defenseman Slater Koekkoek (29) advances the puck through the neutral zone during the first period of Saturday???‚??„?s (10/21/17) game between the Tampa Bay Lightning and the Pittsburgh Penguins at Amalie Arena in Tampa.
  3. Spain planning to strip Catalonia of its autonomy

    World

    BARCELONA, Spain — The escalating confrontation over Catalonia's independence drive took its most serious turn Saturday as Prime Minister Mariano Rajoy of Spain announced he would remove the leadership of the restive region and initiate a process of direct rule by the central government in Madrid.

    Demonstrators in Barcelona protest the decision to take control of Catalonia to derail the independence movement.
  4. Funeral held for soldier at center of political war of words (w/video)

    Nation

    COOPER CITY — Mourners remembered not only a U.S. soldier whose combat death in Africa led to a political fight between President Donald Trump and a Florida congresswoman but his three comrades who died with him.

    The casket of Sgt. La David T. Johnson of Miami Gardens, who was killed in an ambush in Niger. is wheeled out after a viewing at the Christ The Rock Church, Friday, Oct. 20, 2017  in Cooper City, Fla. (Pedro Portal/Miami Herald via AP) FLMIH102
  5. Chemical industry insider now shapes EPA policy

    Nation

    WASHINGTON — For years, the Environmental Protection Agency has struggled to prevent an ingredient once used in stain-resistant carpets and nonstick pans from contaminating drinking water.

    This is the Dow chemical plant near Freeport, Texas. Before the 2016 election, Dow had been in talks with the EPA to phase out the pesticide chlorpyrifos, which is blamed for disabilities in children. Dow is no longer willing to compromise.